pentobarbital will decrease the extent or effect of artemether/lumefantrine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Coadministration with strong CYP3A4 inducers may lead to lessened serum concentrations and lack of antimalarial efficacy
pentobarbital will minimize the level or effect of elbasvir/grazoprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic influence of elbasvir/grazoprevir could be lowered if coadministered with potent CYP3A inducers and it is thus contraindicated.
pentobarbital will decrease the extent or result of quinine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unidentified.
pentobarbital will reduce the level or impact of losartan by impacting hepatic enzyme CYP2C9/10 metabolism. Slight/Significance Mysterious.
Continuously monitor critical indicators throughout sedation and recovery time period if coadministered. Thoroughly titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
Following oral or parenteral administration, barbiturates conveniently cross the placental barrier and they are distributed through fetal tissues with greatest concentrations found in the placenta, fetal liver, and Mind; fetal blood levels approach maternal blood ranges following parenteral administration
With therapeutic doses of TCAs, barbiturates raise metabolism and reduce blood concentrations of TCAs.
pentobarbital will lessen the level or effect of suvorexant by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. Solid CYP3A4 inducers might decrease suvorexant efficacy; if amplified suvorexant dose needed, tend not to exceed 20 mg/working day
To reduce the opportunity of overdosage or the development of dependence, limit the prescribing and dispensing of sedative-hypnotic barbiturates, to the amount needed for the interval until another appointment
pentobarbital will reduce the level or result of dexamethasone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will lower the extent or impact of triazolam by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
Observe Carefully (one)pentobarbital will minimize the extent or effect of glecaprevir/pibrentasvir by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will reduce the extent or result of parecoxib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unidentified.
pentobarbital will lessen the extent or effect of tofacitinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track pentobarbital sale near me of. Loss of, or decreased reaction to tofacitinib may possibly take place when coadministered with strong CYP3A4 inducers